207 related articles for article (PubMed ID: 27902884)
41. (Inverse) Agonists of Retinoic Acid-Related Orphan Receptor γ: Regulation of Immune Responses, Inflammation, and Autoimmune Disease.
Jetten AM; Cook DN
Annu Rev Pharmacol Toxicol; 2020 Jan; 60():371-390. PubMed ID: 31386594
[TBL] [Abstract][Full Text] [Related]
42. Modes of action insights from the crystallographic structures of retinoic acid receptor-related orphan receptor-γt (RORγt).
Zhang J; Chen B; Zhang C; Sun N; Huang X; Wang W; Fu W
Eur J Med Chem; 2023 Feb; 247():115039. PubMed ID: 36566711
[TBL] [Abstract][Full Text] [Related]
43. Rationally Designed, Conformationally Constrained Inverse Agonists of RORγt-Identification of a Potent, Selective Series with Biologic-Like in Vivo Efficacy.
Marcoux D; Duan JJ; Shi Q; Cherney RJ; Srivastava AS; Cornelius L; Batt DG; Liu Q; Beaudoin-Bertrand M; Weigelt CA; Khandelwal P; Vishwakrishnan S; Selvakumar K; Karmakar A; Gupta AK; Basha M; Ramlingam S; Manjunath N; Vanteru S; Karmakar S; Maddala N; Vetrichelvan M; Gupta A; Rampulla RA; Mathur A; Yip S; Li P; Wu DR; Khan J; Ruzanov M; Sack JS; Wang J; Yarde M; Cvijic ME; Li S; Shuster DJ; Borowski V; Xie JH; McIntyre KW; Obermeier MT; Fura A; Stefanski K; Cornelius G; Hynes J; Tino JA; Macor JE; Salter-Cid L; Denton R; Zhao Q; Carter PH; Dhar TGM
J Med Chem; 2019 Nov; 62(21):9931-9946. PubMed ID: 31638797
[TBL] [Abstract][Full Text] [Related]
44. Discovery of Biaryl Amide Derivatives as Potent, Selective, and Orally Bioavailable RORγt Agonists for Cancer Immunotherapy.
Lu L; Huang Y; Song M; Sun N; Xia L; Yu M; Zhao M; Qiu R; Chen JA; Zhao Y; Wang H; Guo H; Li Y; Zhu D; Wang Y; Xie Q
J Med Chem; 2023 Dec; 66(23):16091-16108. PubMed ID: 37982494
[TBL] [Abstract][Full Text] [Related]
45. Synthesis and biological evaluation of 5-(fluoro-substituted-6-methylpyridin-2-yl)-4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)imidazoles as inhibitors of transforming growth factor-β type I receptor kinase.
Krishnaiah M; Jin CH; Sheen YY; Kim DK
Bioorg Med Chem Lett; 2015 Nov; 25(22):5228-31. PubMed ID: 26483198
[TBL] [Abstract][Full Text] [Related]
46. Optimizing a Weakly Binding Fragment into a Potent RORγt Inverse Agonist with Efficacy in an in Vivo Inflammation Model.
Carcache DA; Vulpetti A; Kallen J; Mattes H; Orain D; Stringer R; Vangrevelinghe E; Wolf RM; Kaupmann K; Ottl J; Dawson J; Cooke NG; Hoegenauer K; Billich A; Wagner J; Guntermann C; Hintermann S
J Med Chem; 2018 Aug; 61(15):6724-6735. PubMed ID: 29990434
[TBL] [Abstract][Full Text] [Related]
47. Inhibition of Interleukin-23-Mediated Inflammation with a Novel Small Molecule Inverse Agonist of ROR
Gauld SB; Jacquet S; Gauvin D; Wallace C; Wang Y; McCarthy R; Goess C; Leys L; Huang S; Su Z; Edelmayer R; Wetter J; Salte K; McGaraughty SP; Argiriadi MA; Honore P; Luccarini JM; Bressac D; Desino K; Breinlinger E; Cusack K; Potin D; Kort ME; Masson PJ
J Pharmacol Exp Ther; 2019 Oct; 371(1):208-218. PubMed ID: 31375639
[TBL] [Abstract][Full Text] [Related]
48. Structure-Based Design, Synthesis, and Biological Evaluation of Imidazo[4,5-b]Pyridin-2-one-Based p38 MAP Kinase Inhibitors: Part 2.
Kaieda A; Takahashi M; Fukuda H; Okamoto R; Morimoto S; Gotoh M; Miyazaki T; Hori Y; Unno S; Kawamoto T; Tanaka T; Itono S; Takagi T; Sugimoto H; Okada K; Lane W; Sang BC; Saikatendu K; Matsunaga S; Miwatashi S
ChemMedChem; 2019 Dec; 14(24):2093-2101. PubMed ID: 31697454
[TBL] [Abstract][Full Text] [Related]
49. AT-rich-interactive domain-containing protein 5A functions as a negative regulator of retinoic acid receptor-related orphan nuclear receptor γt-induced Th17 cell differentiation.
Saito Y; Kagami S; Sanayama Y; Ikeda K; Suto A; Kashiwakuma D; Furuta S; Iwamoto I; Nonaka K; Ohara O; Nakajima H
Arthritis Rheumatol; 2014 May; 66(5):1185-94. PubMed ID: 24782182
[TBL] [Abstract][Full Text] [Related]
50. Discovery of novel N-sulfonamide-tetrahydroquinolines as potent retinoic acid receptor-related orphan receptor γt inverse agonists for the treatment of autoimmune diseases.
Sun N; Ma X; Zhou K; Zhu C; Cao Z; Wang Y; Xu J; Fu W
Eur J Med Chem; 2020 Feb; 187():111984. PubMed ID: 31881455
[TBL] [Abstract][Full Text] [Related]
51. Identification of N-sulfonyl-tetrahydroquinolines as RORc inverse agonists.
Fauber BP; Gobbi A; Savy P; Burton B; Deng Y; Everett C; La H; Johnson AR; Lockey P; Norman M; Wong H
Bioorg Med Chem Lett; 2015 Oct; 25(19):4109-13. PubMed ID: 26321361
[TBL] [Abstract][Full Text] [Related]
52. In vivo regulation of gene expression and T helper type 17 differentiation by RORγt inverse agonists.
Skepner J; Trocha M; Ramesh R; Qu XA; Schmidt D; Baloglu E; Lobera M; Davis S; Nolan MA; Carlson TJ; Hill J; Ghosh S; Sundrud MS; Yang J
Immunology; 2015 Jul; 145(3):347-56. PubMed ID: 25604624
[TBL] [Abstract][Full Text] [Related]
53. Discovery of novel N-sulfonamide-tetrahydroisoquinolines as potent retinoic acid receptor-related orphan receptor γt agonists.
Ma X; Sun N; Li X; Fu W
Eur J Med Chem; 2021 Oct; 222():113585. PubMed ID: 34118722
[TBL] [Abstract][Full Text] [Related]
54. Novel non-sulfonamide 5-HT
Vanda D; Soural M; Canale V; Chaumont-Dubel S; Satała G; Kos T; Funk P; Fülöpová V; Lemrová B; Koczurkiewicz P; Pękala E; Bojarski AJ; Popik P; Marin P; Zajdel P
Eur J Med Chem; 2018 Jan; 144():716-729. PubMed ID: 29291439
[TBL] [Abstract][Full Text] [Related]
55. Identification and structure activity relationships of quinoline tertiary alcohol modulators of RORγt.
Kummer DA; Cummings MD; Abad M; Barbay J; Castro G; Wolin R; Kreutter KD; Maharoof U; Milligan C; Nishimura R; Pierce J; Schalk-Hihi C; Spurlino J; Urbanski M; Venkatesan H; Wang A; Woods C; Xue X; Edwards JP; Fourie AM; Leonard K
Bioorg Med Chem Lett; 2017 May; 27(9):2047-2057. PubMed ID: 28318945
[TBL] [Abstract][Full Text] [Related]
56. Discovery of 2,6-difluorobenzyl ether series of phenyl ((R)-3-phenylpyrrolidin-3-yl)sulfones as surprisingly potent, selective and orally bioavailable RORγt inverse agonists.
Duan JJ; Jiang B; Lu Z; Stachura S; Weigelt CA; Sack JS; Khan J; Ruzanov M; Wu DR; Yarde M; Shen DR; Zhao Q; Salter-Cid LM; Carter PH; Murali Dhar TG
Bioorg Med Chem Lett; 2020 Oct; 30(19):127441. PubMed ID: 32736080
[TBL] [Abstract][Full Text] [Related]
57. N(alpha)-imidazolylalkyl and pyridylalkyl derivatives of histaprodifen: synthesis and in vitro evaluation of highly potent histamine H(1)-receptor agonists.
Menghin S; Pertz HH; Kramer K; Seifert R; Schunack W; Elz S
J Med Chem; 2003 Dec; 46(25):5458-70. PubMed ID: 14640554
[TBL] [Abstract][Full Text] [Related]
58. (1H-imidazo[4,5-c]pyridin-2-yl)-1,2,5-oxadiazol-3-ylamine derivatives: further optimisation as highly potent and selective MSK-1-inhibitors.
Bamford MJ; Bailey N; Davies S; Dean DK; Francis L; Panchal TA; Parr CA; Sehmi S; Steadman JG; Takle AK; Townsend JT; Wilson DM
Bioorg Med Chem Lett; 2005 Jul; 15(14):3407-11. PubMed ID: 15955699
[TBL] [Abstract][Full Text] [Related]
59. Discovery of tetrahydroquinolines and benzomorpholines as novel potent RORγt agonists.
Xia Y; Yu M; Zhao Y; Xia L; Huang Y; Sun N; Song M; Guo H; Zhang Y; Zhu D; Xie Q; Wang Y
Eur J Med Chem; 2021 Feb; 211():113013. PubMed ID: 33272782
[TBL] [Abstract][Full Text] [Related]
60. Discovery of tert-amine-based RORγt agonists.
Qiu R; Yu M; Gong J; Tian J; Huang Y; Wang Y; Xie Q
Eur J Med Chem; 2021 Nov; 224():113704. PubMed ID: 34303081
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
